CONGRESS 2023 - Molar pregnancy and gestational trophoblastic disease – why the hCG assay matters

Last updated: 21st September 2023

In this presentation, Imran Jabbar, will delve into the crucial topic of measuring human chorionic gonadotrophin (hCG) in gestational trophoblastic disease (GTD). With a focus on trophoblastic tumours, Imran will explore the significance of hCG as a diagnostic and monitoring tool in GTD. The presentation will cover the principles behind hCG measurement techniques, including immunoassays and molecular methods. Imran will highlight the challenges and advancements in accurately quantifying hCG levels, and discuss their clinical implications. Attendees will gain insights into the role of hCG measurement in early detection, disease monitoring, and prognostic evaluation, ultimately contributing to improved patient outcomes in GTD management.

Download as vCalendar (for Microsoft Outlook etc.)

Import event to your Google Calendar

27th September 2023
Venue: The International Convention Centre (ICC), Birmingham
Learning outcomes

Delegates will:

  • Understand the pathophysiology of molar pregnancy and gestational trophoblastic disease.
  • Understand the use of serum and uring hCG in diagnosis and monitoring of molar pregnancy, choriocarcinoma and other forms of gestational trophoblastic disease.
  • Understand the purpose of the National GTD Screening Service.
  • Understand why it is important that the hCG measurements are carried out on an identified assay.
  • Be aware of the use of hCG measurements in predicting chemotherapy resistance.